CRON Fundamental Analysis - CRONOS GROUP INC

Fundamental Rating

We assign a fundamental rating of 5 out of 10 to CRON. CRON was compared to 35 industry peers in the Pharmaceuticals industry. While CRON has a great health rating, there are worries on its profitability. While showing a medium growth rate, CRON is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

CRON had positive earnings in the past year.

CRON had a positive operating cash flow in the past year.

In the past 5 years CRON reported 4 times negative net income.

In the past 5 years CRON reported 4 times negative operating cash flow.

1.2 Ratios

CRON's Return On Assets of 4.29% is amongst the best of the industry. CRON outperforms 88.57% of its industry peers.

CRON has a better Return On Equity (4.64%) than 88.57% of its industry peers.

		Industry Rank	Sector Rank
ROA	4.29%
ROE	4.64%
ROIC	N/A

ROA(3y)-5.62%

ROA(5y)-9.8%

ROE(3y)-5.87%

ROE(5y)-10.3%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

With an excellent Profit Margin value of 39.68%, CRON belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.

In the last couple of years the Profit Margin of CRON has declined.

CRON has a worse Gross Margin (27.65%) than 62.86% of its industry peers.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	39.68%
GM	27.65%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5Y-62.81%

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

CRON does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, CRON has more shares outstanding

Compared to 5 years ago, CRON has more shares outstanding

CRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

CRON has an Altman-Z score of 6.62. This indicates that CRON is financially healthy and has little risk of bankruptcy at the moment.

The Altman-Z score of CRON (6.62) is better than 97.14% of its industry peers.

CRON has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	6.62

ROIC/WACCN/A

WACC8.43%

2.3 Liquidity

A Current Ratio of 27.80 indicates that CRON has no problem at all paying its short term obligations.

With an excellent Current ratio value of 27.80, CRON belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.

A Quick Ratio of 26.75 indicates that CRON has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 26.75, CRON belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	27.8
Quick Ratio	26.75

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

CRON shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 285.71%, which is quite impressive.

CRON shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -50.78% yearly.

The Revenue has grown by 33.92% in the past year. This is a very strong growth!

Measured over the past years, CRON shows a very strong growth in Revenue. The Revenue has been growing by 37.71% on average per year.

EPS 1Y (TTM)285.71%

EPS 3YN/A

EPS 5Y-50.78%

EPS Q2Q%300%

Revenue 1Y (TTM)33.92%

Revenue growth 3Y16.47%

Revenue growth 5Y37.71%

Sales Q2Q%27.58%

3.2 Future

CRON is expected to show a very negative growth in Earnings Per Share. In the coming years, the EPS will decrease by -21.14% yearly.

The Revenue is expected to grow by 1.87% on average over the next years.

EPS Next Y-144.2%

EPS Next 2Y-9.67%

EPS Next 3Y-39.52%

EPS Next 5Y-21.14%

Revenue Next Year20.49%

Revenue Next 2Y12.81%

Revenue Next 3Y7.09%

Revenue Next 5Y1.87%

3.3 Evolution

The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 15.72, CRON is valued correctly.

88.57% of the companies in the same industry are more expensive than CRON, based on the Price/Earnings ratio.

CRON's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 27.03.

With a Price/Forward Earnings ratio of 25.17, CRON can be considered very expensive at the moment.

Based on the Price/Forward Earnings ratio, CRON is valued a bit cheaper than 74.29% of the companies in the same industry.

When comparing the Price/Forward Earnings ratio of CRON to the average of the S&P500 Index (36.28), we can say CRON is valued slightly cheaper.

		Industry Rank	Sector Rank
PE	15.72
Fwd PE	25.17

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A cheap valuation may be justified as CRON's earnings are expected to decrease with -39.52% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-9.67%

EPS Next 3Y-39.52%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

CRON does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

CRONOS GROUP INC

TSX:CRON (8/5/2025, 7:00:00 PM)

2.83

+0.14 (+5.2%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)05-08 2025-05-08/bmo

Earnings (Next)08-07 2025-08-07/bmo

Inst Owners13.12%

Inst Owner ChangeN/A

Ins Owners6.2%

Ins Owner ChangeN/A

Market Cap1.09B

Analysts76

Price Target2.4 (-15.19%)

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)0

Avg Revenue beat(2)-7.6%

Min Revenue beat(2)-14.99%

Max Revenue beat(2)-0.21%

Revenue beat(4)2

Avg Revenue beat(4)-0.3%

Min Revenue beat(4)-14.99%

Max Revenue beat(4)9.73%

Revenue beat(8)4

Avg Revenue beat(8)0.25%

Revenue beat(12)4

Avg Revenue beat(12)-4.65%

Revenue beat(16)7

Avg Revenue beat(16)-2.62%

PT rev (1m)0%

PT rev (3m)-34.81%

EPS NQ rev (1m)0%

EPS NQ rev (3m)-500.6%

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)0%

Revenue NQ rev (3m)-4.17%

Revenue NY rev (1m)1.73%

Revenue NY rev (3m)1.73%

Valuation

		Industry Rank	Sector Rank
PE	15.72
Fwd PE	25.17
P/S	6.36
P/FCF	N/A
P/OCF	41.8
P/B	0.74
P/tB	0.8
EV/EBITDA	N/A

EPS(TTM)0.18

EY6.36%

EPS(NY)0.11

Fwd EY3.97%

FCF(TTM)-0.03

FCFYN/A

OCF(TTM)0.07

OCFY2.39%

SpS0.45

BVpS3.81

TBVpS3.55

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	4.29%
ROE	4.64%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	39.68%
GM	27.65%
FCFM	N/A

ROA(3y)-5.62%

ROA(5y)-9.8%

ROE(3y)-5.87%

ROE(5y)-10.3%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5Y-62.81%

GM growth 3YN/A

GM growth 5YN/A

F-Score6

Asset Turnover0.11

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	253.86%
Cap/Sales	21.28%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	27.8
Quick Ratio	26.75
Altman-Z	6.62

F-Score6

WACC8.43%

ROIC/WACCN/A

Cap/Depr(3y)70.04%

Cap/Depr(5y)158.35%

Cap/Sales(3y)6.62%

Cap/Sales(5y)22.42%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)285.71%

EPS 3YN/A

EPS 5Y-50.78%

EPS Q2Q%300%

EPS Next Y-144.2%

EPS Next 2Y-9.67%

EPS Next 3Y-39.52%

EPS Next 5Y-21.14%

Revenue 1Y (TTM)33.92%

Revenue growth 3Y16.47%

Revenue growth 5Y37.71%

Sales Q2Q%27.58%

Revenue Next Year20.49%

Revenue Next 2Y12.81%

Revenue Next 3Y7.09%

Revenue Next 5Y1.87%

EBIT growth 1Y32.67%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next Year98.02%

EBIT Next 3Y27.54%

EBIT Next 5Y9.95%

FCF growth 1Y92.98%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y118.45%

OCF growth 3YN/A

OCF growth 5YN/A

CRONOS GROUP INC (CRON.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens